Drug Trial Radar · NCT06000657
Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir
Last checked: Nov 20, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
196
Actual
Start
Aug 28, 2023
Primary completion
Feb 3, 2025
Study completion Feb 3, 2025
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Enroll patients who are pre-treated with Entecavir at least 24 weeks and confirmed HBV antiviral (HBV DNA \<69 IU/mL) effects. Subjects are given one test drug or comparator once a day for 48 weeks according to the results of random assignments, and their HBV antiviral inhibitory effect and safety are evaluated at 24 and 48 weeks visits.
Conditions
- Hepatitis B, Chronic
Interventions
Vemliver tabletDrug
Chronic Hepatitis B Patients Who Pretreated with Entecavir switching to Vemliver tab (Tenofovir Alafenamide Hemitartrate)
Baracross TabletDrug
Chronic Hepatitis B Patients Who Pretreated with Entecavir continuting treatement with Baracross Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- HBV viral suppression rateTime frame: 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.